BDAZ - That was a a very clear and concise answer. I will go with option B, a low probability of Top Line Results coming out this year. Someone in the last few weeks wrote the trial was designed for 2400 patient years and the FDA said they want to see 3300 patient years or 700 more. If the company was expecting to have Top Line Results out in Q4 and you add 700 patient years  and your getting about 7.1 patient years per day at full enrolment then January or February of 2019 is a reasonable bet IMO.

tada